Abstract
This review illustrates a comparison of currently implemented strategies and the need of a novel technique to cure the COVID-19. Current strategies served a lot to cope up with the situation by decreasing the rate of fatalities i.e. some FDA approved drugs and giving immunity by the plasma proteins of cured patients, however these approaches could not eliminate the pandemic from the society emphasizing that some advance technology need to be considered in order to fight with SARS-COV-2 virus. CRISPR-Cas based approach to inactivate the virus before its fusion with host DNA has been successful in in-vitro studies performed at Stanford University along with SHERLOCK & MAMMOTH biosciences who were able to degrade 80 % viral genome. Here we have also done a literature review of major affected countries China, Italy, United states, and India.
Key Words
CRISPR-Cas, Cure, Covid-19, FDA, SARS-COV-2
Introduction
Ever since the man first lay his feet in this world the process of natural selection is going on to keep check and balance between earth resources and the man utilizing them side by side sometimes with natural disasters like floods, volcano eruptions ,earthquakes etc. and sometimes with Epidemic and Pandemic diseases like Cholera ,Influenza ,Typhus, small pox, Measles, leprosy, Polio ,Malaria, HIV and now COVID 19. The 2019 novel coronavirus (2019-nCoV) also known as the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is rapidly spreading from its origin in Wuhan City of Hubei Province of China to the rest of the world and affecting a significant world’s population. The infection has spread in more than 200 countries and territories [1]. Till 16/10/2020 around 39,418,121 cases of coronavirus disease 2019 (COVID-19) and 1,106,128 deaths have been reported [1]. This review article gives a bird’s eye view about the effect of virus on different age groups and gender as well as a comparison of conventional and advanced treatment strategies. Fortunately, children have been least affected by COVID 19, but the future course of this virus is unknown. Data from China, United States, Italy, and India was collected and presented in this review article in tabular or graphical form.
Strategies to Combat COVID-19
To combat COVID-19 numerous strategies are under consideration as well as some are already applied. i.e. around 300 different ways to cope up with this disease and more than 200 vaccines are under clinical trials at various stages, However, traditional approaches look like lagging behind the age to fight the SARS-COV-2 even the antiviral therapy. On the contrary Monoclonal antibodies and Vaccination are promising but still many hurdles needed to be passed on. An accurate diagnostic and treatment approach against COVID-19 is far above the current approaches e.g. clinical trials of vaccines on large scale to develop safety & efficacy profile and financial burden on R & D of Antivirals and industrial production hinders the path to eradicate COVID-19.
CRISPR-Cas associated gene editing technology to visualize and then target the genome of corona virus can be a promising lead in this scenario.
Advanced Technique of CRISPR-CAS Based Strategy for Corona
Clustered regularly interspaced short palindromic repeats (CRISPR) and proteins associated with it together constitute a family of sequences of DNA present in certain prokaryotic Organisms in their genomes i.e. bacteria and archaea. Immune system of such pathogens is characterized with these proteins and helps to provide protection against RNA from phages, DNA, plasmids, or other DNA elements that invade their body. Viral genetic material gets destroyed upon binding with a specific target sequence that is present on specific crRNA produced in response to the invasion of foreign substance to the body. Clinical virology has entered a new era by the discovery of this technique to eliminate the RNA and DNA based viruses and even detection and identification of specific sequence of nucleotides is already under use.
SHERLOCK biosciences were able to detect the S gene and Orf1ab while MAMMOTH Biosciences did target N and E viral genes facilitating the visual readout of the Corona virus genome [13]. After that many techniques have proven successful to diagnose SARS-COV-2 even in < 40 minutes by the CRISPR based lateral flow assay. CRISPR/Cas-NER assay demonstrated 100 percent agreement with PCR in diagnosis of COVID-19 with the success probability of p <0.001.
In a recent study [14], researchers were able to degrade 80-90% of the genetic material of SARS-CoV-2 using a pool of Cas13d (RNA Targeting CRISPR from Class II) and crRNA by targeting multiple regions on the genome of coronavirus. This Technology was coined the name PAC-MAN (Prophylactic Antiviral CRISPR in huMAN cells). It led to the fact that a pool of 6 crRNA could target all the strains of Coronaviruses.
Selective and Efficient Delivery of CRISPR-Cas13 in Antiviral Therapy
The main obstacle in the application of this technique is the delivery of the components of CRISPR to the viral genome. Current method to deliver the CRISPR is non specific means target the both infected as well as normal cells that can cause harmful side effects even in the absence of Viral RNA. Thus there must be some methods that can deliver strategically CRISPR components in to the infected cells only before the testing of this techniques on human level.
One way is to synthesize Cas13 nuclease in such way to have affinity with the viral particles, hence it will deliver the CRISPR components specifically and efficiently into the host cell upon the entrance of the virus itself. In this way the delivery of the virus and the treatment will follow the same path. CRISPR-cas complex will shred the RNA of the virus when it will be released into the host cell cytoplasm by the virus, so the Viral RNA will be cleaved before its translation and replication inside the host cell nucleus. Hence the virus itself will be the main key to kill itself selectively and efficiently.
COVID-19 by Area, Age and Gender
The COVID 19 infection which is affecting a significant world’s population is an emerging global health concern. The infection has spread in more than 200 countries and territories affecting more than 12 million people till now. Data from some of the countries were collected and presented in this article in tabular or graphical form.
China
Wuhan the city of China was the place where the virus started spreading. It was identified in December 2019 in Wuhan however the first case traced back to November 17, 2019.
Figure 1
Graphical Representation of Number of Cases and Deaths within Different Age Groups in China
According to WHO COVID 19 dashboard data, there was an almost linear relationship between total COVID 19 cases and the number of new reported from April till July. The initial spread was very fast making the number in December from a few hundred to the end of January at almost 12,000 and then at the end of February, there were 79,000 cases after that the spread is limited. There were 84,784 COVID 19 cases in China until 25 July.
A total of 72,314 individuals were diagnosed with COVID-19 as of February 11, 2020. 44,672 cases (61.8%) were the confirmed cases, 16,186 cases (22.4%) were suspected, 889 cases (1.2%) were asymptomatic, and 10,567 cases (14.6%) were clinically diagnosed(Zhi, 2020). Most numbers of patients were 30 to 79 years of age (87%), 10 to 19 years of age were (1%), and 3% were age 80 years or older. Most of the cases were diagnosed in Hubei (75%)
Figure 2
Comparison of Percentage of COVID Cases and Deaths among Males and Females of China
and most Wuhan related exposures (86%) [2]. Among 44,672 confirmed cases in China, 22,981 (51.4%) were the males and 21,691 (48.6%) were the females. The male to female ratio was 1.06:1 in China overall while in Wuhan it was 0.99:1 [3].
United States
A study was conducted which was published in JAMA (The Journal of American Medical Association) on April 15, 2020, in which they had studied that almost more than 50% cases were from the Chicago and in those 50% the percentage of the deaths accounted for more than 70% of black people, although blacks were almost 30 percent of the total population.
In Louisiana, 70.5 percent of deaths accounted for black people who represent 32.2 percent of the state population
The Johns Hopkins University and American Community Survey indicated that out of 131 predominantly black people regions in the USA the infection rate was 137.5 out of 100,000 people simply 0.1375% and the death rate was 6.3 out of 100,000 people which was 0.0063%.
The World Health Organization declared the COVID-19 outbreak a pandemic on March 11, 2020. Among the 1,761,503 cases reported to CDC from January 22–May 30, individual case reports for 1,406,098 were submitted to CDC case surveillance.
Table 1. Percentage of Covid-19 Cases within Different Age Groups
Age Group (yrs.) |
No.
of Cases |
Percentage |
0-9 |
20,458 |
1.5 |
10-19 |
49,245 |
3.7 |
20-29 |
182,469 |
13.8 |
30-39 |
214,849 |
16.3 |
40-49 |
219,139 |
16.6 |
50-59 |
235,774 |
17.9 |
60-69 |
179,007 |
13.6 |
70-79 |
105,252 |
8 |
80+ |
114295 |
8.7 |
All Ages |
1,320,488 |
100.0 |
Figure 3
Graphical Representation of no of Cases within Different Age Groups in United States
Table 2. Number of Cases and Deaths among
Males and Females in United States
Sex |
No. of Cases |
Deaths |
Deaths (%age) |
Males |
646,358 |
38,773 |
6.0 |
Females |
674,130 |
32,343 |
4.8 |
Italy
Italy being the part of Europe was
also not safe from the terrorizing effects of COVID 19, till February 2020
there were only 3 cases of COVID 19 and all of those which were traveled to
china recently on February 2020 a person with aggravated pneumonia due to COVID
19 was diagnosed in northern Italy Lombardy region who was in his 30s and
had no history of abroad within 2 weeks many other cases were reported then it
was hypothesized the virus was in population since January 2020 but became
active in February 2020 [5].
Figure 4
Graphical Representation of Number of Cases Among Various Age Groups in Italy
The
overall case fatality rate in Italy (7.2%) was three times more than China
(2.3%) and that increasing number was from the people in Italy who were more
than 70 years whereas in China the death rate in people above 70 years of age
was not as much as in Italy and the possible reason can be genetic makeup and
environmental conditions. Chinese people eat more natural
foods thus have a strong immune system which can bypass the virus attack [5].
According to the data collected there were 22,512
active cases in Italy till March 15, 2020 [6], the number increased to 105,792
on April 1, 2020, (2) and according to WHO COVID 19 dashboard data there were
238,159 cases till June 20, 2020 and the numbers were 245,590 cases until July
25, 2020.
According to
Istituto Superiore di Sanità Italy has 235,579 confirmed cases of COVID-19 and
32,722 associated deaths as of June 8, 2020. The median age of cases is 61
years, and more than two-thirds of these patients had diabetes, cardiovascular
diseases. Of the patients who died, 38.4% were aged >70 years, 30.9% were
aged 51 to 70 years, 28.5% were aged 19-50 years, and 2·2% were aged 0-18 years
[7].
Table 3. Percentage of Deaths and CFR Among Various Age Groups in
Italy
Age (years) |
No. of Deaths |
% of Deaths |
CFR* |
0-9 |
4 |
0 |
0.2% |
10-19 |
0 |
0 |
0% |
20-29 |
15 |
0 |
0.1% |
30-39 |
64 |
0.2 |
0.3% |
40-49 |
282 |
0.9 |
0.9% |
50-59 |
1,141 |
3.5 |
2.7% |
60-69 |
3,335 |
10.2 |
10.6% |
70-79 |
8,738 |
26.7 |
26% |
80-89 |
13,384 |
40.9 |
32.6% |
>90 |
5,759 |
17.6 |
30.4% |
Total |
32,722 |
100 |
13.9% |
The spread of
coronavirus in Italy was slightly greater in females as compared to males. As
the chart shows, 54.2% were the females and 46.8% were the males. As of May 26,
2020, a study on 32,000 patients revealed that the fatality rate is much higher
for men. If the mortality rate for female patients was 10.4% the mortality rate
for male patients was 17.7% [8].
India
The
first case reported in India was on Jan 30, 2020. As of June 16, 2020, India
had a total of 344,407 confirmed cases of coronavirus and 9,921 deaths(Coronavirus |
42% of patients in India between 21 and 40 years, 2020). The
Union Health Ministry on April 4, 2020, throwing light for the first time on
the demography of the cases in India, and according to that, about 42% of
confirmed COVID-19 in India ware between the ages of 21-40 years old. The
percentage of those who were over age 60 was only 17%. The U.S. Centers for
Disease Control said that 29% of the affected were the age of 20-44 years and
32% were above 60 years. The United States recorded the 279,355 cases and 7,451
deaths compared to the 2,904 cases and 75 deaths as on April 4, 2020 [9].
India Today's Data intelligence Unit on 3rd April
2020 showed 1801 COVID-19 confirmed cases revealed that around 60 percent of
the patients were below 50, so young Indians were at higher risk to get this
disease as compared to other population. Similarly, data also revealed that 17%
of the patients were in their 40s, 21% (376 cases) were in their 20s and 22% (391
cases) were in between 30 and 39 years of age. [10].
Early reports
from countries, such as China and Italy, have shown that the most vulnerable
category affected by COVID-19 is that of older people. But in India, patients
over the age of 60 were only 19% of the total confirmed cases while people aged
80 and older account for less than 2% of the total confirmed cases of COVID-19
[11]. The CFR (Case Fatality rate) among males
was 2.9%, while that for females it was 3.3% in India. As of May 20, 2020, 66%
were the males affected by COVID-19 infection while 34% were the females.
Conventional Strategies to Treat
COVID-19
Figure 5
Graphical Representation of %age of cases in different age groups in India
Limitations
Our study has some limitations as only those countries were included in the study that were most affected while those countries who had minor impact were excluded from the study. Hence the results interpreted including the variation of cases among different age groups and among gender are based on four countries China, Italy, United States and India.
Secondly the application of CRISPR-Cas although looks promising but still itself is a barrier to be implemented on large scale as In-vivo studies and Clinical and Pre-Clinical trials will cost much time and finance.
Conclusion
The future trajectory of this virus is still not clear. From the data, it can be concluded that most of the patients were 30 to 70 years of age. Age is one of the important factors playing a key role in the progression of COVID 19. Different countries have different ratios of young to old age persons. The recovery rate is also higher in countries with a high number of young people as compared to those with a high number of old people. The least affected age group in the world is 0 to 20 years of age. On the other hand, cases in males in China, Italy, and India are more as compared to females while in the United States, females are more affected by COVID 19. Different countries and organizations of the world are trying to discover the treatment of COVID-19 but nobody has succeeded to discover the effective drug or vaccine against this rapidly spreading virus. One of those approaches is targeting the genome of coronavirus by applying CRISPR-Cas associated gene-editing technology.
In the scientific community CRISPR can be a very crucial and important area of research study to explore the disease diagnosis as well as treatment in the future with promising potential. Using this technique, we can develop such Novel drugs to cure a range of diseases for example Alzheimer's, HIV/AIDS, Cancer, HIV and such pandemics like Covid-19.
References
- Coronavirus | 42Percent of patients in India between 21 and 40 years. (2020). India:
- Shinghal, T. (2020). A Review of Coronavirus Disease- 2019 (COVID-19). Nature Public Health Emergency Collection, 281-286.
- Edward Livingston, K. B. (2020). Coronavirus Disease 2019 (COVID-19) in Italy. Jama Network.
- Statista. (2020). Coronavirus (COVID-19) death rate in Italy as of October 6, 2020, by gender and age group. Retrieved from Italy:
- Erin K. Stokes, M., corresponding author,* Laura D. Zambrano, PhD,* Kayla N. Anderson, PhD, Ellyn P. Marder, DrPH, Kala M. Raz, MPH, Suad El Burai Felix, MPH, Yunfeng Tie, PhD, and Kathleen E. Fullerton, MPH. (2020). Coronavirus Disease 2019 Case Surveillance. Retrieved from United States:
- Times, T. N. Y. (2020). Does Covid-19 Hit Women and Men Differently? U.S. Isn't Keeping Track.
- Graziano Onder, G. R., Silvio Brusaferro. (2020). Case- Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. Jama Network.
- Timothy R. Abbott, G. D., Yanxia Liu, Xueqiu Lin, Laine Goudy, Leiping Zeng, Augustine Chemparathy, Stephen Chmura, Nicholas S. Heaton, Robert Debs, Tara Pande, Drew Endy, Marie La Russa, David B. Lewis, Lei S. Qi. (2020). Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza. bioRxiv. Worldometer.
- Konwarh, R. (2020). Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches. Frontiers in Molecular Biosciences.
- Zhi, Z. L. X. B. X. Z. (2020). The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. National Library of Medicine, 145-151.
- Rai, D. (2020). Young Indians comprise more than half of confirmed Covid-19 cases. New Delhi:
- Zunyou Wu, M., Jennifer M. McGoogan. (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Jama Network.
- Saeid Chekani-Azar, E. G. M., Mastewal BIRHAN and Mahshad YOUSEFI. (2020). CRISPR/Cas9 gene editing technology and its application to the coronavirus. Journal of Life Science and Biomedicine.
- Samarasinghe, D. A., Nalawansha, Kusal T. G. (2020). Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. ACS Publications, 790-800.
Cite this article
-
APA : Umair-Ul-Hassan., Khan, R. M. A., & Shafiq-Ur-Rehman. (2020). Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries. Global Drug Design & Development Review, V(I), 25-32. https://doi.org/10.31703/gdddr.2020(V-I).03
-
CHICAGO : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. 2020. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review, V (I): 25-32 doi: 10.31703/gdddr.2020(V-I).03
-
HARVARD : UMAIR-UL-HASSAN., KHAN, R. M. A. & SHAFIQ-UR-REHMAN. 2020. Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries. Global Drug Design & Development Review, V, 25-32.
-
MHRA : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. 2020. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review, V: 25-32
-
MLA : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review, V.I (2020): 25-32 Print.
-
OXFORD : Umair-Ul-Hassan, , Khan, Rana Muhammad Awais, and Shafiq-Ur-Rehman, (2020), "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries", Global Drug Design & Development Review, V (I), 25-32
-
TURABIAN : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review V, no. I (2020): 25-32. https://doi.org/10.31703/gdddr.2020(V-I).03